Skip to main content
Fig. 2 | BMC Infectious Diseases

Fig. 2

From: Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort

Fig. 2

Probability of switching from TDF to TAF. Adjusted odds ratios (aOR) and 95% confidence intervals (CI) in study population without (Panel a) and with risk factors for TDF-associated toxicity (Panel b). aOR Adjusted odds ratio, HBV Hepatitis B virus, HCV Hepatitis C virus, CV Cardiovascular disease, eGFR Estimated glomerular filtration rate, PI Protease inhibitor, ART Antiretroviral treatment, NNRTI Non-nucleoside reverse transcriptase inhibitor

Back to article page